← Back to Search

Treatment for Huntington's Disease

N/A
Recruiting
Led By Bernhard G Landwehrmeyer, MD, PhD
Research Sponsored by CHDI Foundation, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial is enrolling over 20,000 participants with the goal of collecting clinical data and biospecimens in order to develop tools for progression and prognosis of Huntington's disease, as well as establish endpoints for interventional studies.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Cognitive Assessments: Symbol Digit Modality Test; Stroop Color Naming; Stroop Word Reading; Categorical Verbal Fluency
Functional Assessments: UHDRS '99 Total Functional Capacity, UHDRS '99 Functional Assessment Scale, UHDRS '99 Independence Scale
Motor Assessments: Unified Huntington's Disease Rating Scale (UHDRS) 99 Motor, UHDRS '99 Diagnostic Confidence Level
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Find a Location

Who is running the clinical trial?

CHDI Foundation, Inc.Lead Sponsor
16 Previous Clinical Trials
4,024 Total Patients Enrolled
Bernhard G Landwehrmeyer, MD, PhDPrincipal InvestigatorUniversity of Ulm
1 Previous Clinical Trials
55 Total Patients Enrolled
Jamie LeveyStudy DirectorCHDI Foundation, Inc.
~23333 spots leftby Jan 2062